Study Recommends Double-J Stent for Enhanced Outcomes in Staghorn Stone Treatment via Percutaneous Nephrolithotomy

Iran: A recent study published in BMC Urology has raised important questions about the necessity of using a double-J stent (DJ stent) after complete supine percutaneous nephrolithotomy (csPCNL) in adult patients with staghorn renal stones. Staghorn stones are large, branched calculi that can significantly impair kidney function and lead to severe complications if not treated effectively. 

The researchers suggest that while omitting a double-J stent after csPCNL can yield acceptable outcomes, the higher residual stone rates associated with staghorn stones lead to increased incidences of renal colic, longer hospital stays, and extended recovery periods. Therefore, they recommend the insertion of a DJ stent.

The research highlights that while csPCNL has become a popular minimally invasive technique for managing these complex stones, postoperative management remains a critical discussion topic. Traditionally, placing a DJ stent following the procedure has been standard practice. The stent maintains urinary drainage, reduces the risk of complications, and adds to patient discomfort and recovery time.

Against the above background, Samira Kazemi, Guilan University of Medical Sciences, Rasht, Iran, and colleagues compared the outcomes of ureteral catheters versus double-J stents in tubeless complete supine PCNL for staghorn stone treatment.

For this purpose, the researchers conducted an analytical cross-sectional study from May 2008 to August 2022, assessing 123 patients who underwent tubeless csPCNL. The patients were categorized into two groups: those who received a double-J (DJ) stent (Group I; n = 23) and those who had a totally tubeless approach using only a perioperative ureteral stent (Group II; n = 100). The study compared demographic characteristics, stone-related factors, and perioperative and postoperative parameters between the two groups.

The following were the key findings of the study:

  • Baseline characteristics were similar across both groups. However, the operative time for Group I was significantly longer than for Group II (68.26 versus 55.25 minutes).
  • In contrast, the duration of hospitalization was shorter for Group I (1.81 versus 2.37 days).
  • The stone-free rate was higher in Group I (90.5% versus 79.8%), although this difference was not statistically significant.
  • There were no major complications between the groups.
  • Patients in Group II experienced a significantly shorter time to return to normal activities (6.48 versus 7.91 days).
  • Multivariable linear regression analysis indicated that preoperative creatinine levels and stone size significantly affect operative time. However, the number of stones and underlying health conditions influenced the length of hospital stay.

“While the necessity of a DJ stent in PCNL for staghorn stones remains debated, its use is advised for these patients due to benefits such as shorter hospital stays, quicker recovery times, and improved success rates,” the researchers concluded.

Reference:

Falahatkar, S., Esmaeili, S., Kazemi, S. et al. Is double-J stent mandatory in complete supine percutaneous nephrolithotomy for adult patients with staghorn renal stones? BMC Urol 24, 216 (2024). https://doi.org/10.1186/s12894-024-01610-9

Powered by WPeMatico

Cycling may improve physical function and reduce hospital stays among critically ill patients, finds study

A new systematic review led by researchers in Hamilton, Canada has shown that specialized in-bed cycling therapy, when used in the intensive care unit with critically ill patients, leads to better physical function and a one-day shorter length of stay in the ICU.

The review showed on average, patients who cycled spent one day less in the ICU compared to those who didn’t, and 1.5 days less in the hospital overall, freeing up an important bed sooner. , the average costs per patient can be up to $7,300 per ICU day and $1,500 per hospital day.

Traditionally, ICU rehabilitation studies have been inconclusive or lacked clear results. With this systematic review, a clearer picture is emerging around the safety and benefits of cycling as a rehabilitation intervention in the ICU.

The research – published in NEJM Evidence and simultaneously announced at the European Society of Intensive Care Medicine Congress in Spain – was led by researchers with McMaster University’s School of Rehabilitation Science and St. Joseph’s Healthcare Hamilton. The review analyzed data from 33 rehabilitation clinical trials in 13 countries and included nearly 3,300 patients.

“This research is a major win for patients and their families,” said Heather O’Grady, lead author and recent PhD graduate from Rehabilitation Science at McMaster. “This analysis shows that cycling as part of rehabilitation in the ICU can decrease ICU and overall hospital length of stay, is safe and perhaps most importantly for patients, leads to better physical function post-ICU discharge.”

The review builds off previous research conducted by senior author Michelle Kho, a professor with McMaster’s School of Rehabilitation Science, that first highlighted the potential benefits of cycling by patients in the ICU.

In addition to the main findings, the review showed that adverse events during cycling are uncommon, occurring in less than one per cent of patients. Importantly, patients who received cycling in the ICU did not have higher mortality than those in the comparison groups.

The researchers say the findings provide a distinct research pathway for future study because the model of rehabilitation uses clear-cut equipment, is reproducible and easily standardized.

Reference:

 Heather K. O’Grady, Hibaa Hasan, Bram Rochwerg, Deborah J. Cook, Alyson Takaoka, Rucha Utgikar, Julie C. Reid, and Michelle E. Leg Cycle Ergometry in Critically Ill Patients-An Updated Systematic Review and Meta-Analysis, NEJM Evidence, doi/full/10.1056/EVIDoa2400194.

Powered by WPeMatico

Twice-Yearly Depemokimab Effectively Lowers Exacerbation Rates in Severe Eosinophilic Asthma: Study Reveals

USA: A recent study published in the New England Journal of Medicine highlights the effectiveness of Depemokimab, an innovative monoclonal antibody, in managing severe asthma among patients with an eosinophilic phenotype.

The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma exacerbations, offering hope for better disease management.

Eosinophilic asthma, characterized by elevated eosinophil levels in the airways, often leads to more severe symptoms and frequent exacerbations compared to other asthma phenotypes. Traditional treatments may not always provide adequate relief, prompting the need for targeted therapies like Depemokimab, which specifically aims to reduce inflammation associated with eosinophils. Depemokimab is a long-acting biologic therapy with improved binding affinity for interleukin-5, potentially allowing for effective dosing every six months.

In this context, David J. Jackson, the King’s College London, London, and colleagues assessed the efficacy and safety of depemokimab in patients with severe asthma characterized by an eosinophilic phenotype. This phenotype was defined by a high eosinophil count (≥300 cells per microliter in the past 12 months or ≥150 cells per microliter at screening) and a history of exacerbations despite receiving medium- or high-dose inhaled glucocorticoids. The evaluation was conducted through phase 3A, randomized, placebo-controlled trials known as SWIFT-1 and SWIFT-2.

Patients were randomly assigned in a 2:1 ratio to receive either 100 mg of depemokimab administered subcutaneously or placebo at weeks 0 and 26, along with standard care. The primary endpoint was the annualized rate of exacerbations at 52 weeks. Secondary endpoints, analyzed hierarchically to account for multiple comparisons, included changes from baseline in the St. George’s Respiratory Questionnaire (SGRQ) scores, forced expiratory volume in one second (FEV1), and reports of asthma symptoms at 52 weeks.

The researchers reported the following findings:

  • Across the two trials, 792 patients were randomized, with 762 included in the full analysis—502 received depemokimab and 260 received placebo.
  • In the SWIFT-1 trial, the annualized rate of exacerbations was 0.46 for the depemokimab group compared to 1.11 for the placebo group, resulting in a rate ratio of 0.42.
  • In SWIFT-2, the annualized rates were 0.56 for depemokimab and 1.08 for placebo, yielding a rate ratio of 0.52.
  • No significant differences in the change from baseline in SGRQ scores were found in either trial, precluding statistical inferences for subsequent secondary endpoints.
  • In both trials, adverse event occurrence was comparable between the two groups.

The findings showed that depemokimab decreased the annualized rate of exacerbations in patients with severe asthma characterized by an eosinophilic phenotype.

“The study’s outcomes signal a promising advancement in asthma care, especially for those suffering from the eosinophilic form of the disease. With ongoing research and potential regulatory approvals on the horizon, Depemokimab could soon become a vital tool in the fight against severe asthma,” the researchers concluded.

Reference:

Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID; SWIFT-1 and SWIFT-2 Investigators. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024 Sep 9. doi: 10.1056/NEJMoa2406673. Epub ahead of print. PMID: 39248309.

Powered by WPeMatico

Aerobic Physical Activity Linked to Reduced Depression in Cancer Patients: JAMA

Canada: A recent systematic review and meta-analysis have shed light on the positive effects of aerobic physical activity (APA) on depression among patients with cancer.

The research, published in JAMA Network Open, revealed that APA was linked to modest reductions in depression both in the short term and long term among adults with cancer. The researchers advise recommending aerobic physical activity to adults with cancer as a means to help reduce depression.

Depression is a common and debilitating condition that affects many individuals diagnosed with cancer. The emotional toll of a cancer diagnosis, along with the physical side effects of treatment, often exacerbates feelings of hopelessness and anxiety. Traditional therapeutic approaches for managing depression may not be sufficient on their own, prompting researchers to explore complementary strategies, such as physical activity.

While aerobic physical activity is recognized as an effective strategy for managing depression in the general population, its effectiveness in alleviating depressive symptoms among cancer patients needs further investigation. To fill this knowledge gap, Matthew Kulchycki, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada, and colleagues aimed to assess whether APA reduces the severity of depression in cancer patients by synthesizing data from published randomized clinical trials (RCTs).

For this purpose, the researchers systematically searched six databases for relevant citations published from January 1, 1980, to July 5, 2023. This systematic review and meta-analysis included RCTs that compared APA interventions with usual care, waitlist control, or attention control for managing depression in cancer patients, regardless of age or cancer type.

Two reviewers independently conducted the screening and data extraction, assessing the risk of bias using the Cochrane Risk of Bias Tool, version 2, while adhering to the PRISMA guidelines. Standardized mean differences (SMDs) were calculated using a random-effects model. Data collection and analyses took place from June 2022 to March 2024.

The primary outcome measured was the severity of self-reported depression within one-month post-intervention (short-term). Secondary outcomes included depression severity between one and six months post-intervention (medium-term) and between six and twelve months post-intervention (long-term).

The meta-analysis included 25 randomized controlled trials (RCTs) involving 1,931 adults with cancer aged 18 to 80 years. Based on the study, the researchers reported the following findings:

  • Among these studies, ten RCTs exhibited a low risk of bias.
  • Aerobic physical activity was associated with a reduction in self-reported depression among the participants (SMD, −0.3).
  • The reduction in depression scores was statistically significant for long-term outcomes in three trials (n = 299 participants; SMD, −0.32).
  • There was no significant impact on medium-term depression across two trials (n = 143 participants; SMD, −0.27.

The findings of the review highlight the importance of prioritizing trials focused on understudied populations, such as children with cancer and individuals with metastatic disease. This approach is essential for gaining a more comprehensive understanding of the potential benefits of aerobic physical activity in alleviating depression within these groups.

“Future research should also explore the effectiveness of APA in conjunction with other strategies for managing depression among diverse cancer patient populations,” the researchers concluded.

Reference:

Kulchycki M, Halder HR, Askin N, et al. Aerobic Physical Activity and Depression Among Patients With Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(10):e2437964. doi:10.1001/jamanetworkopen.2024.37964

Powered by WPeMatico

Serratiopeptidase with diclofenac sodium effective for pain after day care obstetric and gynaecological surgeries: Study

Postoperative pain is a major complication after surgery
which can affect functional recovery and also diminish patients’ overall
quality of life. Inflammation plays critical role in the postoperative pain
pathophysiology. Due to surgical procedures tissue damages and inflammatory
cells proliferate at the surgical site, generating inflammatory mediators that
induce tissue inflammation. Analgesic or anaesthetic measures are used to
inhibit the potential transition from acute to chronic postoperative pain.
These measures reduce the frequency and intensity of acute pain during and immediately
after surgery. Current treatment strategies in the postoperative pain
management includes the usage of systemic non-opioid and opioid pain relievers,
along with analgesics, peripheral nerve blockers, and, as per the need, the
utilization of additional pharmaceutical agents to alleviate pain.

The attention of surgeons has been focused on the elements
of patient care that can be improved in the light of the modern emphasis on
managed care and shorter hospital stays. Reducing or even eliminating post-operative
pain, without introducing excessive sedation, promotes rapid mobilization and
return to autonomy. Targeted multimodal pain management can reduce
postoperative ileus and other adverse reactions to analgesics.

One proteolytic enzyme that has been used to lessen
inflammation is serratiopeptidase. Because of its antiinflammatory and
anti-edema qualities, enteric coated oral formulations of this enzyme are
frequently used in a variety of specialties, including surgery, orthopaedics,
otolaryngology, gynecology, and dentistry. When used in conjunction with
surgery, nonsteroidal anti-inflammatory drugs, or NSAIDs, have demonstrated
their efficacy as analgesics, as evidenced by either a decrease in pain scores
or an opioid sparing effect. Diclofenac is one of the NSAIDs commonly
prescribed for pain relief. Although the efficacy and safety of
Serratiopeptidase and Diclofenac Sodium has been proven in few randomized
clinical trials, data regarding the effectiveness of this combination for
relief of symptoms in clinical practice settings in obstetric and
gynaecological surgeries, are scarce. Therefore, based on a retrospective
pooled analysis of data in clinical practice settings, Bapat et al. aimed to
assess the fixed dose combination (FDC) of Serratiopeptidase (10 mg) with
Diclofenac Sodium (50 mg) in day care obstetric and gynaecological surgeries in
daily practice.

This was a single centre, retrospective, observational data
collection in reallife scenario. Data of adult women who had undergone day care
OBG surgery and received a FDC of Serratiopeptidase (10 mg) with Diclofenac
Sodium (50 mg) gastro-resistant tablets TID for period of 24 hours was
retrieved and analysed. VAS (Visual Analogue Scale) data on post-operative pain
at rest and pain on movement as well as post-operative swelling were analyzed
in conjunction with monitoring for adverse events.

Among 61 patient’s data included in the study, 40 (65.57%)
had undergone Minimally Invasive Vaginal Hysterectomy (MIVH), 4 (6.56%) had
MIVH with Bilateral Salpingo-oophorectomy, and 17 (27.87%) had other OBG
surgeries. The average VAS scores for pain at rest (VAS), pain on movement
(VAS) and swelling were significantly reduced compared to baseline at all-time
points (p>0.001). Clinical global impression of efficacy and safety for 95%
physician’s and 93.3% patients was good to very good. FDC was found to be well
tolerated without any serious adverse reaction.

Postoperative pain is the major concern in surgeries of
obstetrics and gynaecology department and it is associated with the highest
severity. So it is highly essential to improve the postoperative pain management
in minor surgeries. For certain patients, postoperative pain control still
requires improvement despite advancements in pharmacology and surgical techniques.
Inadequate management of pain following surgery is linked to longer hospital
stays, ER visits, and readmissions. Insufficient postoperative pain control
also leads to the development of chronic pain. Multi-modal pain management
strategy along with reduction in swelling is needed in post obstetric and
gynaecological surgeries.

Serratiopeptidase is a proteolytic enzyme excreted by
non-pathogenic Enterobacteria serratia isolated from intestine of silkworms
Bombyx mori L Serratiopeptidase exhibits notable analgesic, anti-inflammatory,
and antiedema characteristics. This enzyme was discovered to be used for pain,
inflammation brought on by trauma, and surgery. It reduces inflammation in
three ways: by breaking down blood coagulation-related insoluble protein
byproducts, by thinned inflammation- and injury-related fluids, and by speeding
up tissue repair. It lessens pain by preventing the amines that cause pain. It
also aids in healing by dissolving the dead tissue that surrounds the wounded
area. Moreover, serratiopeptidase functions by altering adhesion molecules on
the cell surface. Serratiopeptidase is not addictive and does not result in
hazardous internal bleeding like NSAID painkillers do. Its application lies in
its ability to suppress and eradicate hemorrhage following surgery.

It was found that this enzyme is used for pain relief. It
breaks down protein deposits like fibrin in the human body. This is a safe,
natural substitute for NSAIDs and steroids that doesn’t have any negative side
effects.

A FDC of an effective proteolytic enzyme, Serratiopeptidase
and a potent NSAID Diclofenac, complement the action of each other by
inhibiting the release of bradykinin and blocking production of prostaglandins.
It is approved for use as a pharmaceutical ingredient in India to treat acute
pain in conjunction with other medications. This combination not only controls
inflammation but also helps in the clearance of exudates and improving
microcirculation.

The use of enzymes in medical therapy has been limited. Serratiopeptidase
has revealed interesting applications in the field of pain management.
Serratiopeptidase has a remarkable record of safety from decades of use by
millions of users all around the world. Authors did not record any serious
adverse events in our study either. Serratiopeptidase dosage recommendations
range from 10 mg to 30 mg daily. It is commonly known that serratiopeptidase
reduces pain by preventing the release of molecules that cause pain from
inflammatory tissues. Enzymes have a higher affinity and specificity for their
targets, which allows them to convert multiple target molecules into desired
products. As a result, enzymespecific drugs have been developed to treat a wide
range of disorders.

Results of this study provides direct clinical evidence of
the efficacy and safety of FDC of Serratiopeptidase and Diclofenac sodium in
day care obstetric and gynaecological surgeries in reducing post-operative pain
and swelling in the early post-operative period.

Source: Bapat et al. / Indian Journal of Obstetrics and
Gynecology Research 2024;11(3):442–446

Powered by WPeMatico

New AI model may accurately diagnose periodontal bone loss and periodontitis from dental panoramic radiographs: Study

A new AI model may accurately diagnose periodontal bone loss and periodontitis from dental panoramic radiographs suggests a study published in the Journal of Dentistry.

Artificial intelligence (AI) could be used as an automatically diagnosis method for dental disease due to its accuracy and efficiency. This research proposed a novel convolutional neural network (CNN)-based deep learning (DL) ensemble model for tooth position detection, tooth outline segmentation, tooth tissue segmentation, periodontal bone loss and periodontitis stage prediction using dental panoramic radiographs. The dental panoramic radiographs of 320 patients during the period January 2020 to December 2023 were collected in our dataset. All images were de-identified without private information. In total, 8462 teeth were included. The algorithms that DL ensemble model adopted include YOLOv8, Mask R-CNN, and TransUNet. The prediction results of DL method were compared with diagnosis of periodontists.Results: The periodontal bone loss degree deviation between the DL method and ground truth drawn by the three periodontists was 5.28%. The overall PCC value of the DL method and the periodontists’ diagnoses was 0.832 (P <​ 0.001). ​The ICC value was 0.806 (P <​ 0.001). The total diagnostic accuracy of the DL method was 89.45%.The proposed DL ensemble model in this study shows high accuracy and efficiency in radiographic detection and a valuable adjunct to periodontal diagnosis. The method has strong potential to enhance clinical professional performance and build more efficient dental health services. The DL method not only could help dentists for rapid and accurate auxiliary diagnosis and prevent medical negligence, but also could be used as a useful learning resource for inexperienced dentists and dental students.

Reference:

Xue T, Chen L, Sun Q. Deep learning method to automatically diagnose periodontal bone loss and periodontitis stage in dental panoramic radiograph. J Dent. 2024 Sep 26;150:105373. doi: 10.1016/j.jdent.2024.105373. Epub ahead of print. PMID: 39332519.

Keywords:

New, AI, model, accurately, diagnose, periodontal, bone loss, periodontitis, dental, panoramic, radiographs, study, Xue T, Chen L, Sun Q, Journal of Dentistry Computer-aided diagnosis; Deep learning; Periodontal bone loss; Periodontitis stage.

Powered by WPeMatico

Study Finds U-Shaped Link Between TyG-BMI and Mortality Risks in Osteoarthritis Patients, Highlighting IR Role

China: A recent analysis of National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2020 has unveiled a U-shaped nonlinear relationship between the triglyceride glucose-body mass index (TyG-BMI) and both all-cause and cardiovascular mortality among adults with osteoarthritis (OA) in the United States.

The findings, published in Scientific Reports, highlight the complex role that insulin resistance (IR) plays in the health outcomes of these patients.

“Mortality risks escalated when TyG-BMI levels exceeded thresholds of 282 for all-cause mortality and 270 for cardiovascular mortality. For each 10-unit increase above these thresholds, there was a corresponding 3% rise in the risk of all-cause mortality and a 5% increase in cardiovascular mortality risk,” the researchers reported.

The TyG-BMI index, a composite measure combining triglyceride levels, glucose levels, and body mass index, has been increasingly recognized for its potential in assessing metabolic health and the risk of adverse outcomes. The relationship between insulin resistance and all-cause and cardiovascular mortality risk in osteoarthritis patients is still unclear. Considering this, Wenbo Ding, China Medical University, Liaoning, People’s Republic of China, and colleagues aimed to clarify the correlation between a novel marker of IR, the TyG-BMI index, and the risk of all-cause mortality and cardiovascular mortality in OA patients.

For this purpose, the researchers analyzed data from the NHANES covering 1999 to 2020. They used multivariable Cox proportional hazards regression analysis and restricted cubic spline plots to investigate the relationship between the TyG-BMI index and all-cause and cardiovascular mortality risk among osteoarthritis patients. To further refine their findings, subgroup analyses were performed to examine potential interactions and identify populations at higher mortality risk.

The study included a cohort of 4,097 OA patients who were followed for 20 years, during which 1,197 cases of all-cause mortality and 329 cases of cardiovascular mortality were documented.

The following were the key findings of the study:

  • There was a U-shaped nonlinear relationship between the TyG-BMI index and the risk of all-cause mortality or cardiovascular mortality in OA patients, with the lowest mortality risk thresholds identified at 282 and 270, respectively.
  • Surpassing these thresholds was associated with a 3% increase in the risk of all-cause mortality and a 5% increase in the risk of cardiovascular mortality for every 10-unit increment in TyG-BMI level.

The study reveals a U-shaped nonlinear relationship between TyG-BMI levels and all-cause and cardiovascular mortality in osteoarthritis (OA) patients, identifying a specific TyG-BMI index threshold associated with the lowest mortality risk. This finding offers clinicians a new perspective and potential intervention target for identifying and addressing OA patients at higher mortality risk.

“The research highlights the value of the TyG-BMI index in assessing insulin resistance (IR) to predict OA patient outcomes and suggests that insulin therapy could benefit these patients,” the researchers concluded.

Reference:

Wang, W., Zhou, F., Li, Y., Liu, Y., Sun, H., Lv, Q., & Ding, W. (2024). U-shaped association between triglyceride glucose-body mass index with all-cause and cardiovascular mortality in US adults with osteoarthritis: Evidence from NHANES 1999–2020. Scientific Reports, 14(1), 1-10. https://doi.org/10.1038/s41598-024-70443-1

Powered by WPeMatico

Premature newborn’s hand amputated due to negligence! Hospital, Doctor slapped Rs 45 Lakh Compensation

Amritsar: The District Consumer Disputes Redressal Commission, Amritsar recently directed a city-based private hospital and its doctor to pay Rs 45 lakh compensation and Rs 1 Lakh legal cost to a man for alleged medical negligence while providing treatment to his newborn child.

After being born prematurely, the child was admitted to the hospital as he was suffering from a low oxygen level. However, during treatment, gangrene formed in his right hand leading to the amputation of the hand at PGI Chandigarh.

The history of the case goes back to 2020 when the complainant’s son was born. At the time of birth, his oxygen level was very low and accordingly, the newborn was admitted to the treating hospital on 22.08.2020.

As per the complainant, during the medical treatment of the newborn, the treating doctors put the wrong drip on his right hand due to which his hand became blue. Consequently, the child’s right arm became damaged due to impending gangrene and alleged wrongful treatment provided by the treating hospital and doctors. 

It was alleged that after being admitted to the hospital for some days, the newborn was arbitrarily discharged. Following this, he was admitted to PGI Chandigarh, where after proper diagnosis, his right hand was amputated by the treating doctors of PGI Chandigarh in order to save his life.

Alleging medical negligence on the part of the treating doctor and hospital, the complainant sought Rs 45 lacs compensation, and Rs 2 lacs as litigation expenses.

On the other hand, the doctor and hospital argued that the complainant did not explain how they were negligent in providing treatment to the minor child. According to them, no medical expert was examined to prove that they were negligent in the treatment provided to the complainant’s son.

As per the doctor and hospital, the child was put on ventilator support and oxygen for altogether 15 days and showed improvement and started digesting feeds. However, since the child was pre-term with very low immunity, he developed sepsis for which he was being given the required antibiotics. On the 20th day of admission, the child’s condition suddenly deteriorated and the attendants were informed and advised to take the baby to a centre for further investigations and treatment of the hand. Accordingly, the treating doctor talked to the Paediatric Intensivist at Fortis Hospital for immediate care of the child, but the attendants acted negligently and refused to take the child to Fortis Hospital and insisted on continuing the treatment from the treating hospital only. Again, the attendants were suggested to take the baby to Fortis or PGI Chandigarh or any other higher institute of their choice, they submitted.

It was submitted that the child was initially taken to another hospital, where no proper facilities were available and was taken to PGI Chandigarh only after a delay of a few days.

Delay in getting the appropriate treatment to prevent the loss of hand was due to sheer negligence of parents and other family members who did not take their baby directly to Fortis Hospital or PGI as per medical advice given by them, argued the treating doctor and hospital.

While considering the matter, the District Consumer Court took note of the report by the Asstt. Civil Surgeon, Amritsar dated 09.07.2021, which stated, “In conclusion the medical board has given its opinion that the aforesaid complication was caused due to inadvertently and Dr. *** has promised that when the child grown up he will get arrangement of artificial limb/hand.”

Referring to this report, the Commission observed, “So a bare reading of the report given by Medical board, it stands proved that the opposite parties No.1 & 2 ( the hospital and the doctor) have admitted their fault and only given explanation that the whole episode done due to inadvertently. So all amounts to negligence which has been analysed in Halsbury’s Laws of England (4th Edition) Volume 34…”

“So far as medical negligence is concerned it was the duty of the medical professionalists to take due care while treating the patient much less the patient is of a tender age. It is admitted that patient was referred to them as it was a premature delivery of the child and this child was required utmost care which as per allegations of the complainant the opposite parties have failed to provide to the minor son of the complainant. Heavy onus is upon the hospital when it alleges that they are not negligent to give treatment to the son of the complainant and to prove that they have discharged their duty with due care,” it further noted.

Relying on the legal precedence set by the Supreme Court regarding issues concerning medical negligence, the District Consumer Court Amritsar held the treating hospital and doctor guilty of negligence in providing treatment to the complainant’s son.

In respect to the amount of compensation, the Commission held that the compensation demanded by the Complainant i.e. Rs 45 lacs was “very very less than the mental agony whatsoever the complainant and his family suffered at the hands of the opposite parties and the minor son of the complainant become handicapped due to the negligence of the opposite parties and his present as well as future life is also affected due to the act of the opposite parties.”

Accordingly, the Commission ordered, “Hence, the opposite parties No.1 & 2 are directed to pay compensation of Rs. 45 lacs and Rs. 1,00,000/- as litigation expenses to the complainant. It is also ordered that since the welfare of the child is involved in the present case and keeping in view the peculiar circumstances of the case, the entire amount of Rs. 45 lacs as compensation and Rs. 1,00,000/- as litigation expenses which is to be given to the complainant being the guardian of the minor child and he will convert the same into the FDR in the name of the minor son of the complainant till he attains age of 21 years.” 

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/amritsar-dcdrc-256428.pdf
Also Read: Medical Negligence during Cataract Surgery: Jaipur’s Eye Hospital, Doctor directed to pay Rs 16.6 Lakh Compensation

Powered by WPeMatico

JIPMER Invites Application for SR Post In Various Departments, View All Details Here

Puducherry: The Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER Puducherry) has invited online applications for the post of Senior Resident on a contract basis in different departments in this institute.

JIPMER became an institution of national importance under the Ministry of Health and Family Welfare, Government of India in the year 2008. JIPMER offers various undergraduate and postgraduate medical courses. Located in Pondicherry, JIPMER is also a fully functional hospital that provides medical treatments to patients from all over the world. It has about 200 faculty members 3,000 staff and 360 resident physicians.

JIPMER Puducherry Vacancy Details:

Total no of vacancies: 46

The vacancies are in the Departments of Anaesthesiology, Anatomy, Biochemistry, Emergency Medicine, General Medicine, General Surgery, Microbiology, Nuclear Medicine, Ophthalmology, Orthopaedics, Paediatrics, Pharmacology, Physical Medicine & Rehabilitation, Physiology, Preventive and Social Medicine, Psychiatry, Pulmonary Medicine, Radiation Oncology, and Radiology.

The last date of submission of online application is 28th October 2024 till 04.30 PM.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=JIPMER&location=&job_sector=all

Eligible Candidates (How to Apply):-

APPLICATION – REGISTRATION & SUBMISSION

SUBMISSION OF APPLICATION: THROUGH ON-LINE MODE ONLY.

1. Candidates are informed to apply on-line mode only. (Any other mode of applications will not be accepted / considered)

2. Log on to link in the Home page https://jipmer.edu.in/ and click “Apply on-line to the post of Senior Resident on Contract basis at JIPMER, Puducherry”.

(OR)

Candidate should click the following link (Ctrl + Click) or copy and paste the URL in Google chrome / Internet explorer / Mozilla Firefox. https://forms.gle/FGT2AcSC8ZBTSN798

3. The candidate should acquaint himself/herself with all requirements with regard to filling up the application on-line.

4. Candidates are advised NOT TO SEND HARD COPY of the application / documents by postal/courier/by hand.

IMPORTANT NOTE Crucial date for determination of eligibility with regards to age and educational qualification etc. will be 05-11-2024. Those who do not fulfill any of the above conditions need not apply. Mere permission to appear in the interview through video-conferencing does not imply any determination of final eligibility.

Candidates are informed to check the JIPMER website i.e. https://jipmer.edu.in/ periodically for any updates.

Also Read:Lady Hardinge Medical College Delhi Recruitment: 76 Junior Resident Vacancies in Various Departments, Apply Now

Powered by WPeMatico

DCI issues advisory for dental colleges on uploading details of BDS, MDS, PG Diploma admissions

New Delhi: Through a recent notice, the Dental Council of India (DCI) has released an advisory for dental colleges regarding admissions to BDS /MDS/ PG Diploma Courses.

In the advisory to the Principal/Head of all the Dental Colleges, the Executive Committee of the DCI referred to its observation and stated that in its meeting held on 21.09.2024 has observed that there have been instances, where colleges prematurely upload the details of the students on the DCI portal without completing the actual admission process at their college OR when such student is actually admitted in some other dental colleges, which not only leads to distress the students but also creates confusion for the DCI and for the colleges where the students are genuinely enrolled.

The Executive Committee has also observed that in case of cancellation/discontinuation of course by a student, the college is not informing to the Council timely to delete his/her name from the DCI portal, the council said.

Accordingly,  in order to combat with the problems being faced by the concerned students, colleges and the DCI, it has been decided as under:-

All the dental colleges in the country be directed to upload the details of only the bonafide student on DCI portal after verifying the eligibility and selection criteria prescribed in DCI regulations including

(i) valid allotment letter issued by the concerned counseling authority

(ii) valid fee receipt issued by the concerned college and

(iii) consent of admission by the student on judicial stamp paper, failing which the DCI shall take necessary action against the college as per norms.

It further mentioned, ” all the dental colleges be also directed to intimate this Council within 15 days about cancellation/discontinuation/discharge of any student from the college, failing which, appropriate action shall be taken under the provision of Dentists Act and Regulations made there under”

The above decision of the Executive Committee is communicated for information and strictly compliance.

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/n101024055033516-256387.pdf

Powered by WPeMatico